Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2024 16:30 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 25, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 23, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 19, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 12, 2024 16:05 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 05, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
August 19, 2024 17:12 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
August 13, 2024 16:29 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
July 03, 2024 13:05 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
May 30, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right